tbuckley/cabot-search huggingface dataset:
NET of the lung: The experience of the Italian registry.
Authors: G. Valmadre, R. Epis, M. Robustellini, C. Della Pona, A. Buscemi, S. Artale, M. Dambrosio
Journal: Journal of Clinical Oncology (2010)

e17530 Background: Pulmonary NETS are typical carcinoid (TC), atypical carcinoid (AC), large-cell neuroendocrine carcinoma (LCNC), and SCLC. Purpose: to evalue prognosis of pulmonary well differentiated NET and establish an Italian registry. Methods: From 1996 to 2007 our lung cancer working group followed 51 pulmonary NETs. 2/51 were metastatic at the diagnosis. Results: 44/51 underwent radical surgical resection with adenectomy. 2/51 TC had definitive endobronchial laser, 3/51 had disostructive laser (2/3 followed by bilobectomy). 37/51 (72%) are TC. 11/51 (21%) are AC, 2/51 (4%) undetermined. Results: follow-up at dec 07: 3/51 were lost. 1 AC dead 7 yrs after diagnosis for progressive disease (liver metastasis, high CgA, and 3 yrs of octreotide). 1 undeterminated histology dead 1 yr after diagnosis (high CgA, octreotide therapy). 7 had preoperating CgA: 2 high (1 developed hepatic metastasis, in 1 normalized and 48 mths DFS). 3 TC had progressive disease. 1 TC (IA, high pre-lobectomy CgA), had persistent high CgA and hepatic lesion octreoscan+, 4 mths later: PR after 18 mths of octreotide. 1 TC (IB) with normal pre-lobectomy CgA had carcinoid syndrome with high CgA and octreoscan positivity, 4 mths later: negative restaging at 34 mths with 1 yr of octreotide. A sixteen girl – TC IB – with high CgA (normal after pneumonectomy) developed octreoscan + thoracic lesions, 18 mths later. PR after 56 mths with radiometabolic therapy. Conclusions: NETS are heterogeneous lung cancers. AC radically resected had good prognosis (1/11 metastasis), sometimes TC gave metastasis (2/37). Octreotide- and radiometabolic therapy can control metastatic disease. CgA is not indicative of relapse but correlates with the extension of metastatic disease. High CgA values are not predictive of carcinoid syndrome. It is important to evalue CgA before and 2-3 mths after surgery. From this experience, we have created — since January 08 — an Italian registry of Net of the lung (all histologies). The purpose is to have more data about incidence, prognosis and treatment of this rare disease. At January 09, 23 centers have given their adhesion and 120 cases are reported. We think that is useful the effort of all Italian centers to have more data and increase the knowledge of the disease. No significant financial relationships to disclose.
CT predictors of response to endobronchial valve lung reduction treatment: Comparison with Chartis pulmonary assessment system
Authors: Maren Schuhmann, Daniela Gompelmann, Ralf Eberhardt, Philippe Raffy, Youbing Ying, Derek Hornberg, Susan Wood, Herth Felix
Journal: European Respiratory Journal (2014)

PURPOSE: Chartis Pulmonary Assessment System™ has shown 75% accuracy in predicting patient response to valve-based lung volume reduction. We compared quantitative CT (QCT) measurements with Chartis in selecting likely responders of valve-based LVR treatment.  METHODS: CT scans of 146 subjects with severe emphysema who underwent endobronchial valve LVR were analyzed retrospectively using dedicated lung quantitative imaging software (Apollo®, VIDA Diagnostics). In 33 patients collateral ventilation was evaluated using Chartis prior to treatment. EBV valves were placed with unilateral complete occlusion. Treated lobe volumes were measured at baseline and 3-months. Volume reduction ≥ 350 cc was considered a positive treatment response. Fissure integrity (FI), Low Attenuation Clusters (LAC), and patient′s percent peripheral vessel volume (PPVV) were previously identified to predict outcome of LVR therapy. QCT-Bayes was assessed vs Chartis in selecting likely responders.  RESULTS: Fissure integrity (FI; p‹0.0001), Low Attenuation Clusters (LAC; p=0.01), and percentage of patient′s peripheral vessel volume (PPVV; p=0.02) were identified as primary QCT predictors of LVR outcome. QCT-Bayes patient-selection method was comparable with Chartis, with identical accuracy of 78.8% (26/33).  CONCLUSION: QCT modeling of endobronchial LVR outcome is a promising tool to effectively select candidates for valve-based LVR.
Transcatheter treatment of heart failure with preserved or mildly reduced ejection fraction using a novel interatrial implant to lower left atrial pressure
Authors: Lars Søndergaard, Vivek Reddy, David Kaye, Filip Malek, Antony Walton, Martin Mates, Olaf Franzen, Petr Neuzil, Nikolaj Ihlemann, Finn Gustafsson
Journal: European Journal of Heart Failure (2014)
Illness and Culture
Authors: Frank A. Lederle
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Poliomyelitis: Papers and Discussions Presented at the Second International Poliomyelitis Conference.
Authors: John R. Paul
Journal: JAMA (1953)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cyclophosphamide-induced hemorrhagic cystitis in Ewing's sarcoma.
Authors: T J Stillwell, R C Benson, E O Burgert
Journal: Journal of Clinical Oncology (1988)

Recent improvements in survival of patients with Ewing's sarcoma have been made since the addition of cyclophosphamide-based adjuvant chemotherapy to primary surgery and radiation. A potential limitation to cyclophosphamide use is its urotoxicity, primarily in the form of hemorrhagic cystitis. The incidence of this adverse effect in patients treated for Ewing's sarcoma has not been established. In a Mayo Clinic series of 116 patients with Ewing's sarcoma treated with cyclophosphamide, 17 (15%) developed hemorrhagic cystitis diagnosed on the basis of gross hematuria or cystoscopic findings (or both). Microscopic hematuria also occurred in 53% of patients (56 of 105 examined). The dose and duration of therapy appeared to be unrelated to the development of urotoxicity. Most patients recovered uneventfully with or without discontinuation of cyclophosphamide therapy, but a significant loss of blood occurred in three patients, and one patient required a cystectomy because of bladder fibrosis. Long-term follow-up is mandatory in these patients because of late recurrences of hemorrhagic cystitis or the possibility of bladder carcinoma. New therapies, directed at protecting the bladder from urotoxicity during cyclophosphamide treatment, are available.
Abstract 1739: Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial
Authors: Melanie Heroult, Peter Ellinghaus, Christian Sieg, Dirk Brohm, Sylvia Gruenewald, Marie-Pierre Collin, Ulf Boemer, Mario Lobell, Walter Huebsch, Matthias Ocker, Stuart Ince, Andrea Haegebarth, Rolf Jautelat, Holger Hess-Stumpp, Michael Brands, Karl Ziegelbauer
Journal: Cancer Research (2014)

Abstract Fibroblast growth factors (FGFs) orchestrate a variety of cellular functions by binding to their transmembrane tyrosine-kinase receptors (FGFR1-4) and activating downstream signaling pathways. FGF signaling has been demonstrated to be altered in a high proportion of cancers, with activating mutations and/or overexpression of FGFRs frequently observed in lung, gastric, breast and urothelial tumors. Therefore, targeting FGFRs using selective FGFR inhibitors is an attractive therapeutic approach to treat cancer patients. BAY 1163877 is as an orally available, selective and potent inhibitor of FGFR-1, -2 and -3 kinase activity. BAY 1163877 has been advanced through preclinical development and we disclose here the first details of its preclinical profile. BAY 1163877 inhibited FGFR-1, -2, -3 kinase activity in the nanomolar range and demonstrated a kinase selectivity profile for FGFR-1, -2 and -3 over 222 kinases tested. BAY 1163877 inhibited proliferation of various cancer cell lines in vitro and phosphorylation of downstream signaling molecules. BAY 1163877 was also tested in vivo in monotherapy and combination therapy on various human xenografts and syngeneic tumors and inhibited growth of tumors presenting at least one FGFR alteration.Overall, the in vitro and in vivo studies confirm that the FGFR inhibitor BAY 1163877 is a potent and selective inhibitor of altered FGFRs pathways in cancer models. A Phase 1 clinical trial (NCT01976741) has been initiated. Citation Format: Melanie Heroult, Peter Ellinghaus, Christian Sieg, Dirk Brohm, Sylvia Gruenewald, Marie-Pierre Collin, Ulf Boemer, Mario Lobell, Walter Huebsch, Matthias Ocker, Stuart Ince, Andrea Haegebarth, Rolf Jautelat, Holger Hess-Stumpp, Michael Brands, Karl Ziegelbauer. Preclinical profile of BAY 1163877 - a selective pan-FGFR inhibitor in phase 1 clinical trial. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 1739. doi:10.1158/1538-7445.AM2014-1739
Intravenous recombinant interferon beta in patients with recurrent malignant gliomas: a phase I/II study.
Authors: W K Yung, M Prados, V A Levin, M R Fetell, J Bennett, M S Mahaley, M Salcman, E Etcubanas
Journal: Journal of Clinical Oncology (1991)

A multicenter phase I/II trial of a human recombinant interferon beta (Betaseron; Triton Biosciences, Alameda, CA) was conducted in patients with recurrent glioblastoma and anaplastic astrocytoma in six centers between 1986 and 1988. Betaseron was given intravenously three times per week, starting at 90 x 10(6) IU per dose and escalating by 90 x 10(6) IU every 2 weeks up to a maximum dose of 540 x 10(6) per treatment. All patients had failed prior radiotherapy, and most had failed one or more courses of chemotherapy. Of the 72 patients entered into the protocol, 65 were considered assessable. Of 65 patients, 41 had glioblastoma, and 24 had anaplastic astrocytoma. Of the 65 assessable patients, 15 (23%) had an objective response (R), and 18 (28%) had stable disease (S), with a combined R and S rate of 51%. The Kaplan-Meier median time to progression was 24 weeks for the responders, 10 weeks for the nonresponders, and 23 weeks for the whole group. These results suggest that Betaseron has definite activity in recurrent gliomas, with an R + S rate of 51%. The maximum-tolerated dose (MTD) is between 180 and 360 x 10(6) IU, with neurotoxicity being the most troublesome toxicity at higher doses. Two patients died of treatment-related complication. Since most responders showed responses at the 180 x 10(6 IU dose range, further studies using a lower dose of Betaseron aimed at decreasing toxicity and allowing chronic maintenance therapy are merited.
STUDIES OF CALCIUM AND PHOSPHORUS METABOLISM
Authors: Joseph C. Aub, Fuller Albright, Walter Bauer, Elsie Rossmeisl
Journal: Journal of Clinical Investigation (1932)

Following the observation by Aub, Bauer, Heath, and Ropes (1), that the thyroid hormone exerts a marked effect upon the excretion of calcium, it became of interest to determine the therapeutic effect of this internal secretion upon the calcium metabolism in tetany.In hyperthyroidism, although the blood calcium and phosphorus levels are essen- tially normal, the calcium and phosphorus excretions are abnormally high.Tetany of the low calcium variety, however, has been shown to have an abnormally low calcium excretion associated with the abnormally low blood calcium level.The primary purpose of these metabolic studies was to study the influence of thyroid medication on the level of calcium and phosphorus in the blood and excreta of patients suffering from tetany.Other observations, however, were made for comparison and this paper includes data illustrating the influence on inorganic salt metabolism of:1. Hypoparathyroidism, 2. Chronic steatorrhea complicated by tetany, 3. The immediate and prolonged use of parathyroid and thyroid medi- cation in the tetany of hypoparathyroidism, and 4. The production of acidosis in the above types of tetany.The data reported in this paper were obtained from three cases of tetany which we observed over prolonged periods.K. L. (Case I) had severe, chronic parathyroid tetany which was precipitated by two radical thyroidectomies for very mild Graves' disease.The tetany eventually could not be controlled, and the patient died.B. W. (Case II) 1 appar- ently had idiopathic parathyroid tetany.DeLaB.(Case III),' a young woman with tetany produced by celiac disease or steatorrhea, was similar to patients reported by Blumgart (2), Thaysen (3), Holmes and Starr (4), Linder and Harris (5), and Hunter (6).The summaries of the case his- tories are attached to the end of this paper.These cases were studied in Cases II and III are further discussed in other papers (9,10,11).
Timing and Duration of Traffic-related Air Pollution Exposure and the Risk for Childhood Wheeze and Asthma
Authors: Kelly J. Brunst, Patrick H. Ryan, Cole Brokamp, David Bernstein, Tiina Reponen, James Lockey, Gurjit K. Khurana Hershey, Linda Levin, Sergey A. Grinshpun, Grace LeMasters
Journal: American Journal of Respiratory and Critical Care Medicine (2015)

The timing and duration of traffic-related air pollution (TRAP) exposure may be important for childhood wheezing and asthma development.We examined the relationship between TRAP exposure and longitudinal wheezing phenotypes and asthma at age 7 years.Children completed clinical examinations annually from age 1 year through age 4 years and age 7 years. Parental-reported wheezing was assessed at each age, and longitudinal wheezing phenotypes (early-transient, late-onset, persistent) and asthma were defined at age 7 years. Participants' time-weighted exposure to TRAP, from birth through age 7 years, was estimated using a land-use regression model. The relationship between TRAP exposure and wheezing phenotypes and asthma was examined.High TRAP exposure at birth was significantly associated with both transient and persistent wheezing phenotypes (adjusted odds ratio [aOR] = 1.64; 95% confidence interval [CI], 1.04-2.57 and aOR = 2.31; 95% CI, 1.28-4.15, respectively); exposure from birth to age 1 year and age 1 to 2 years was also associated with persistent wheeze. Only children with high average TRAP exposure from birth through age 7 years were at significantly increased risk for asthma (aOR = 1.71; 95% CI, 1.01-2.88).Early-life exposure to TRAP is associated with increased risk for persistent wheezing, but only long-term exposure to high levels of TRAP throughout childhood was associated with asthma development.
Monospot and VP1 Tests in Chronic Fatigue Syndrome and Major Depression
Authors: S P J Lynch, R V Seth, J Main
Journal: Journal of the Royal Society of Medicine (1992)

Thirty-four patients with chronic fatigue syndrome (CFS) were compared with controls with DSM-III-R major depression on the Monospot and VP1 antigen tests. There was no significant difference in the numbers initially VP1 positive in the groups (11/34 and 7/34 positive in the chronic fatigue and major depression group respectively). Four CFS but no depressed patients were Monospot positive initially. No patient was both Monospot and VP1 positive. Patients positive on the tests were offered a repeat 6 months later. Eight of the 11 VP1 positive patients in the CFS group were retested and four remained positive, but none of the four depressed patients retested remained positive. No patient retested remained Monospot positive. The Monospot and VP1 tests appear to have little discriminating ability between these groups as screening tests and their predictive validity is unclear.
Diagnostic surgical lung biopsy in hematologic patients with pulmonary complications
Authors: Lilian Junker, Jörg Halter, Franco Gambazzi, Daiana Stolz, Lukas Bubendorf, Spasenija Savic, Dominik Heim, Martin Stern, Christoph Bucher, Didier Lardinois, Michael Tamm
Journal: European Respiratory Journal (2011)

Pulmonary infectious and non-infectious complications are frequent in hematologic patients. If there is antibiotic resistant fever or persistent infiltrates bronchoscopy is performed. However in a considerable number of cases bronchoscopy is inconclusive and lung tissue needed to achieve a definitive diagnosis. We assessed the diagnostic yield and risk of VATS biopsy or open lung biopsy (OLB) in hematologic patients suffering from pulmonary complications. 81 patients with a mean age of 47 years underwent VATS (73%) or OLB (27%) from 2000 to 2010. 49 patients underwent allogeneic and 7 autologous SCT, 21 had high dose chemotherapy. Examinations revealed an infectious agent in 6 (Tbc, 2 PcP, 2 bacterial, echinococcus), bronchiolitis obliterans in 23, organizing pneumonia in 8, diffuse alveolar damage in 8, NSIP in 2, and lymphoma in 3 cases.  There was no perioperative death. A prolonged ICU stay (>72hours) was needed in 11 cases. 5 of these patients were already on the ICU prior to surgery. Re-operation was needed in 6 cases. No wound infection was observed. Thorax drainage was prolonged (> 5d) in 12 patients (15%). One patient developed a pneumothorax 12 days after VATS during a flight. 30-day mortality was 7% (6/81): 4 diffuse alveolar damage, 1 fungal infection/renal failure and 1 OP/renal failure. 2 of the 6 deaths occurred in patients already ventilated prior to surgery.   Summary and conclusion:  The diagnostic yield of lung biopsy in hematologic patients is very high directly affecting patient management. The risk of the surgical procedure itself is acceptable. Mortality is increased in patients ventilated prior to surgery and in those with diffuse alveolar damage on histology.
Spam medicine
Authors: D. Spence
Journal: BMJ (2008)

<h3>Background and objectives</h3> The serratus plane block (SPB) is a novel chest wall interfascial plane block. Its analgesic efficacy compared with non-block care and paravertebral block (PVB) is unestablished. <h3>Methods</h3> We conducted a random-effects meta-analysis of randomized controlled trials (RCTs) recruiting adult surgical patients that compared a SPB to non-block care or PVB for postoperative analgesia. Visual analog scale pain scores were the primary outcome. Database sources were Medline, Embase, the Cochrane Library, and Google Scholar searched up to July 29, 2019 without language restriction. Risk of bias was assessed using Cochrane methodology. <h3>Results</h3> Nineteen RCTs that comprised 1260 patients were included. Six trials involved thoracic surgery patients and 13 studied breast surgery patients. SPB reduced pain scores 0 hour postoperatively (−1.62 cm; 99% CI −2.43 to −0.81; p&lt;0.001; I<sup>2</sup>=92%), at 2–4 hours (−1.29 cm; 99% CI −2.08 to −0.49; p&lt;0.001; I<sup>2</sup>=92%), at 6 hours (−1.69 cm; 99% CI −3.19 to −0.20; p=0.004; I<sup>2</sup>=99%), and up to 24 hours compared with non-block care. SPB also prolonged the time to first analgesic request (193.2 min; 95% CI 7.2 to 379.2 min; p=0.04; I<sup>2</sup>=99%), reduced 24-hour postoperative opioid consumption (−11.27 mg of IV morphine equivalent; −17.36 to −5.18 mg; p&lt;0.001), and reduced postoperative nausea and vomiting (RR 0.51; 95% CI 0.38 to 0.68; p&lt;0.001; I<sup>2</sup>=12%). In contrast, no meaningful differences were detected in any of the outcomes for the SPB versus PVB data. <h3>Conclusions</h3> SPB reduced postoperative pain scores (Grading of Recommendations Assessment, Development, and Evaluation rating: low; due to heterogeneity and deficiencies in blinding) in breast and thoracic surgery patients compared with non-block care. Based on five trials only, SPB was not appreciably different from PVB.
Impaired platelet activation and cAMP homeostasis in MRP4-deficient mice
Authors: Benoit Decouture, Elise Dreano, Tiphaine Belleville-Rolland, Orjeta Kuci, Blandine Dizier, Amine Bazaa, Bérard Coqueran, Anne-Marie Lompre, Cécile V. Denis, Jean-Sébastien Hulot, Christilla Bachelot-Loza, Pascale Gaussem
Journal: Blood (2015)
Abstract 17455: Genetic Deficiency of the H2S Producing Enzyme 3-mercaptopyruvate sulfurtransferase (3-MST) Exacerbates Myocardia Ischemia/Reperfusion (MI/R) Injury
Authors: David Polhemus, Hiroyuki Otsuka, Shashi Bhushan, Adrienne L King, David J Lefer
Journal: Circulation (2013)

Background: Hydrogen Sulfide (H2S) protects against acute myocardial ischemia/reperfusion (MI/R) injury and heart failure by ameliorating oxidative stress, reducing apoptosis, and attenuating infla...
What is new in selective decontamination of the digestive tract?
Authors: Jozef Kesecioglu, Philippe Eggimann
Journal: Intensive Care Medicine (2015)

Selective decontamination of the digestive tract (SDD) and selective oropharyngeal decontamination (SOD) are among the few interventions in intensive care medicine that have been shown to improve patient survival, but their use is limited to a minority of European intensive care units (ICUs) (Tables 1,2) [1].In addition, when the microbiological data of patients receiving SDD or SOD were compared with those receiving standard care, ICU-acquired bacteremia was significantly reduced for Staphylococcus aureus, glucosenon-fermenting Gram-negative rods, and Enterobacteriaceae [4], In particular, the use of SDD was associated with a lower incidence of acquired bacteremia with Enterobacteriaceae.Similarly, ICU-acquired candidemia was lower in the SDD group than in the SOD group or standard care group, but the difference was not significant.These findings were confirmed in a recent study comparing SDD and SOD on antibiotic resistance.The incidence of ICU-acquired bacteremia was also lower for aminoglycoside-resistant Gram-negative bacteria in the SDD group [5].Although the survival rate of ICU patients remains similar in both studies, the lower incidence of antibiotic resistance and nosocomial bacteremia as consistent findings are in favour of SDD.Common reasons for the reluctance to use SDD or SOD are related to only a few arguments regularly mentioned in editorials and by expert opinion expressing the fear that their use may promote antibiotic resistance and the possible increase of methicillin-resistant S. aureus [15].